Author/Authors :
Aydogdu, Aydogan Departments of Endocrinology and Metabolism - Ankara, Turkey , Haymana, Cem Departments of Endocrinology and Metabolism - Ankara, Turkey , Baskoy, Kamil Departments of Endocrinology and Metabolism - Ankara, Turkey , Durukan, Ali H Gulhane School of Medicine - Ankara, Turkey , Ozgur, Gokhan Gulhane School of Medicine - Ankara, Turkey , Azal, Omer Departments of Endocrinology and Metabolism - Ankara, Turkey
Abstract :
We report a case of choroidal neovascularization (CNV) secondary to methylenetetrahydrofolate reductase (MTHFR) gene mutation
in a 20-year-old male patient with hypopituitarism. Treatment with three consecutive injections of intravitreal ranibizumab
(anti-vascular endothelial growth factor) resulted in signifi cant improvement of the patient’s vision and the appearance of the
macula. A search of the literature produced no previously reported case of MTHFR gene mutation associated both CNV and
possibly hypopituitarism. With hormone replacement therapy of hypopituitarism, acetyl salicylic acid 100 mg/day also was
started. Th e patient was clinically stable both for CNV and other thromboembolic disorders over a 6-month follow-up and also
1-year follow-up period.
Keywords :
Choroidal neovascularization , drug therapy , hypopituitarism , intravitreal injections , methylenetetrahydrofolate reductase defi ciency , MTHFR , ranibizumab , vascular endothelial growth factor